Is there an optimal timing interval between hCG trigger and oocyte vitrification?
Copyright © 2022. Published by Elsevier B.V..
OBJECTIVE: Oocyte vitrification has been developed as a promising alternative to slow freezing; however, the clinical outcome is highly operator dependent. From the past study, we know the timing of cryoprotectant exposure and understand that the intervals between the application of liquid nitrogen and thawing solution are crucial factors in the vitrification process. However, the optimal time intervals between hCG trigger and oocyte vitrification and equilibration remain unknown. This study aimed to evaluate the optimal intervals before and during modified vitrification.
MATERIALS AND METHODS: This retrospective study included 66 patients undergoing vitrified-thawed oocyte cycles from June 2018 to May 2019. Oocyte in vitro maturation (IVM) is defined as the maturation in vitro of an immature oocyte collected using a standard pick up procedure. Oocytes were grouped into the following intervals: (1) human chorionic gonadotropin (hCG) trigger to oocyte vitrification (<38 h; 38-39 h; >39 h; IVM) (2) oocyte equilibration time (<10 min; 10-12 min; 12-15 min). The vitrification and warming procedures were performed following the steps as shown in the Cryotec method.
RESULTS: A total of 390 mature oocytes were vitrified with the Cryotec method. The survival rates were not significantly different among the various intervals after the hCG trigger (97.59%; 95.54%; 100%); however, there was a trend of decreased survival rate in IVM group (66.67%). The oocyte survival rates were not significantly different among the various times of oocyte equilibration (96.77%; 97.33%; 95.42%).
CONCLUSIONS: This was the first study to demonstrate no correlation between oocyte survival rate and the time intervals between hCG trigger and oocyte vitrification. Nor did the oocyte survival rate correlate with the various equilibration times during vitrification, as long as the oocyte was mature. In the future, large, prospective, randomized controlled studies will be required to confirm the clinical outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Taiwanese journal of obstetrics & gynecology - 61(2022), 3 vom: 20. Mai, Seite 485-488 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Weng, Yu-Wen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chorionic Gonadotropin |
|---|
| Anmerkungen: |
Date Completed 24.05.2022 Date Revised 03.06.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tjog.2022.03.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341180297 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341180297 | ||
| 003 | DE-627 | ||
| 005 | 20231226011202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tjog.2022.03.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341180297 | ||
| 035 | |a (NLM)35595442 | ||
| 035 | |a (PII)S1028-4559(22)00083-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Weng, Yu-Wen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is there an optimal timing interval between hCG trigger and oocyte vitrification? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2022 | ||
| 500 | |a Date Revised 03.06.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier B.V. | ||
| 520 | |a OBJECTIVE: Oocyte vitrification has been developed as a promising alternative to slow freezing; however, the clinical outcome is highly operator dependent. From the past study, we know the timing of cryoprotectant exposure and understand that the intervals between the application of liquid nitrogen and thawing solution are crucial factors in the vitrification process. However, the optimal time intervals between hCG trigger and oocyte vitrification and equilibration remain unknown. This study aimed to evaluate the optimal intervals before and during modified vitrification | ||
| 520 | |a MATERIALS AND METHODS: This retrospective study included 66 patients undergoing vitrified-thawed oocyte cycles from June 2018 to May 2019. Oocyte in vitro maturation (IVM) is defined as the maturation in vitro of an immature oocyte collected using a standard pick up procedure. Oocytes were grouped into the following intervals: (1) human chorionic gonadotropin (hCG) trigger to oocyte vitrification (<38 h; 38-39 h; >39 h; IVM) (2) oocyte equilibration time (<10 min; 10-12 min; 12-15 min). The vitrification and warming procedures were performed following the steps as shown in the Cryotec method | ||
| 520 | |a RESULTS: A total of 390 mature oocytes were vitrified with the Cryotec method. The survival rates were not significantly different among the various intervals after the hCG trigger (97.59%; 95.54%; 100%); however, there was a trend of decreased survival rate in IVM group (66.67%). The oocyte survival rates were not significantly different among the various times of oocyte equilibration (96.77%; 97.33%; 95.42%) | ||
| 520 | |a CONCLUSIONS: This was the first study to demonstrate no correlation between oocyte survival rate and the time intervals between hCG trigger and oocyte vitrification. Nor did the oocyte survival rate correlate with the various equilibration times during vitrification, as long as the oocyte was mature. In the future, large, prospective, randomized controlled studies will be required to confirm the clinical outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cryopreservation | |
| 650 | 4 | |a Oocyte | |
| 650 | 4 | |a Survival rate | |
| 650 | 4 | |a Vitrification | |
| 650 | 4 | |a hCG trigger | |
| 650 | 7 | |a Chorionic Gonadotropin |2 NLM | |
| 700 | 1 | |a Lin, Ming-Huei |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo-Kuang Lee, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Sheng-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Jou, Quan-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ying Ju |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Taiwanese journal of obstetrics & gynecology |d 2006 |g 61(2022), 3 vom: 20. Mai, Seite 485-488 |w (DE-627)NLM167249967 |x 1875-6263 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:3 |g day:20 |g month:05 |g pages:485-488 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tjog.2022.03.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e 3 |b 20 |c 05 |h 485-488 | ||